On the fee-for-service record this fell to about 0.7× its 2015 level — but MA-adjusted, the total held near 1.0×: a shrinking share, not a shrinking market.
Medicare reported an estimated 6.6 million Nerve Block Injection - Back services in the United States in 2024
In 2024, Medicare's fee-for-service record carried about 3.3 million Nerve Block Injection - Back billed services in the United States; scaled for Medicare Advantage — roughly half of Medicare enrollment — that is an estimated 6.6 million services, or about 116 per 1,000 fee-for-service beneficiaries.
This counts reported Medicare Nerve Block Injection - Back SERVICES — billed services, not procedures, visits, transports, or people. A single episode can bill several services, and one person can be served many times, so this is a volume of billed services and nothing more. On the fee-for-service record the 2024 volume was about 3.3 million billed services; scaled to total Medicare enrollment it is an estimated 6.6 million. Assumption-free, that is about 116 Nerve Block Injection - Back services per 1,000 fee-for-service beneficiaries. Across 2015–2024 the estimated total moved about 1.0 times (about 0.7 times on the fee-for-service record alone, before the Medicare Advantage adjustment).
Reported Medicare fee-for-service Nerve Block Injection - Back billed services, 2015 to 2024, scaled to total Medicare enrollment, with the assumption-free per-1,000-beneficiary rate stated alongside.
Not a count of procedures, visits, transports, or people (a services-volume count — one episode can bill several services), not Medicare Advantage measured directly, not all-payer, and not a care-quality or need signal. The scaled figures are estimates: the calculation assumes MA per-capita utilization ≈ FFS; MA plans may manage utilization differently. The per-1,000 rate is on the fee-for-service record and is not scaled.